The FDA approved Tauklarify on August 14, 2026, as a diagnostic brain scan that detects tau tangles, the sticky protein clumps tied to Alzheimer's disease. It does not treat anything and does not, by itself, diagnose Alzheimer's — it gives a doctor one more piece of evidence to weigh. For someone with mild cognitive impairment (MCI), a stage where memory or thinking problems are noticeable but don't yet stop daily life, that distinction matters. A scan result is information for a clinical conversation, not a verdict.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official notice from Lantheus — Use this primary source to verify the official announcement.
- Read the official guidance from Healio — Use this primary source to verify the official guidance.
Table of Contents
- What Tauklarify Actually Does
- Why the Headline Needs a Second Look
- How Accurate Is the Scan, Really?
- What This Means If You Have MCI
- Frequently Asked Questions
What Tauklarify Actually Does
Tauklarify is the brand name for florquinitau F-18 injection, also sold under the research name MK-6240. It's a radioactive tracer: a doctor injects it into a vein, waits about 90 minutes, then runs a roughly 20-minute PET scan of the brain, according to a company and trade summary reported by Healio. The tracer binds to tau neurofibrillary tangles, the twisted protein fibers that build up inside neurons as Alzheimer's progresses, and lights them up on the scan. The FDA's approval, announced in a Lantheus press release, covers adults with cognitive impairment — including MCI — who are being evaluated for Alzheimer's disease.
Lantheus holds U.S. rights to the drug after acquiring it from Enigma Biomedical USA in 2023, and Enigma issued its own approval announcement the same day. This is the second tau-imaging tracer the FDA has cleared. The first, flortaucipir F-18 (brand name Tauvid, made by Eli Lilly), was approved in 2020, according to the Society of Nuclear Medicine and Molecular Imaging. Having a second validated tracer gives clinicians and imaging centers an alternative, which can matter for availability, scheduling, or scanner compatibility.
Why the Headline Needs a Second Look
The approval headline makes Tauklarify sound like a definitive answer, but the label itself draws a hard line around what the scan can confirm. According to Healio's coverage of the approval, safety and effectiveness have not been established for evaluating tauopathies other than Alzheimer's — meaning the scan isn't validated for other forms of dementia that also involve tau buildup. More importantly, a positive or negative scan doesn't stand on its own.
Regulators and the same Healio report are explicit that the result is "one input alongside clinical evaluation," not an independent diagnosis of Alzheimer's disease. A scan showing tau tangles doesn't mean a person has or will develop Alzheimer's dementia; a doctor still weighs memory testing, other imaging, and the person's history before reaching a conclusion. That gap between what a scan detects and what it proves is where overreading happens. A tau-positive result on an MCI patient is evidence of underlying pathology, not a fixed timeline or a guaranteed diagnosis.
How Accurate Is the Scan, Really?
The FDA's approval rested on two blinded-read studies, each using five independent readers who didn't know the clinical details of the scans they were evaluating. In Study 1, with 279 participants, positive percent agreement — how often readers correctly identified a truly tau-positive scan as positive — ranged from 80% to 88%. In Study 2, with 338 participants, that range dropped to 68% to 82%, according to Healio's report on the trial data. In plain terms: in the weaker-performing study, roughly one in three true positives could have been read as negative. That's a meaningful miss rate, not a rounding error.
Negative results fared better. Negative percent agreement — how reliably a truly tau-negative scan was read as negative — ran 98% to 99% in Study 1 and 93% to 99% in Study 2, per the same Healio summary. A clean negative scan is a stronger piece of evidence against tau pathology than a positive scan is for it. One caveat matters specifically for MCI readers: the trial populations mixed people with MCI, mild Alzheimer's dementia, and cognitively unimpaired volunteers. The accuracy numbers reflect that blend, not MCI patients in isolation, and performance may differ at the earlier, lower tau-burden stage that defines MCI.
What This Means If You Have MCI
If a doctor orders a Tauklarify scan for someone with MCI, the practical questions are what a positive or negative result changes — and what it doesn't. Safety data from 1,734 people showed the procedure itself is low-risk: headache was the most common side effect, reported in about 0.7% of patients, according to the Healio safety summary.
The scan itself is not the hard part — interpreting the result is. A few things to keep in mind when discussing results with a clinician: None of this makes the scan less useful — it's a real tool added to a short list of validated tau tracers. It just means the result functions as one data point in a larger clinical picture, the same way blood pressure or a single lab value informs a diagnosis without being the whole diagnosis.
- A positive scan adds evidence of tau pathology but, given the 68–88% agreement range, isn't a guaranteed confirmation — ask what other testing supports or challenges the result.
- A negative scan is more trustworthy at ruling tau out, given its 93–99% agreement range, but still isn't the sole basis for ruling out Alzheimer's.
- The scan is specifically for Alzheimer's evaluation — it isn't validated for diagnosing other tau-related dementias.
- Ask where the trial accuracy numbers apply to your specific stage, since the studies combined MCI, mild dementia, and unimpaired participants.
Frequently Asked Questions
Is Tauklarify a treatment for Alzheimer's?
No. It's a diagnostic imaging agent injected before a PET scan — it detects tau tangles, it doesn't treat them, per the Enigma Biomedical USA announcement.
Can Tauklarify diagnose dementias other than Alzheimer's?
The FDA label specifically states safety and effectiveness have not been established for other tauopathies, according to Healio's coverage.
Is this the first tau PET scan approved by the FDA?
No. Flortaucipir F-18 (Tauvid) was approved in 2020; Tauklarify is the second, per SNMMI.
You Might Also Like
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
- Day-One Subcutaneous Leqembi for Early Alzheimer’s in 2026: Access, Coverage, and Training Questions for People With Mild Cognitive Impairment
